We use essential cookies to keep Stock Expert AI secure and working. With your consent, we use analytics cookies to understand site usage and improve the experience. Privacy policy
Americold Realty Trust (COLD) is showing positive momentum, with shares up +2.56% following news of its transformational joint venture with EQT Partners. This partnership unlocks $1.1 billion in proceeds, accelerating the company's deleveraging efforts and highlighting a significant public-private valuation gap. Americold is also experiencing gains in its international operations, particularly in Europe, which are driving occupancy and throughput.
Conversely, ImmunityBio (IBRX) is facing headwinds, with shares down -6.72% amid a securities class action lawsuit. The lawsuit follows an FDA warning letter regarding misleading efficacy claims made by the company's executive chairman about its lead biologic product, Anktiva. The FDA's action and subsequent market reaction underscore the importance of regulatory compliance and transparent communication in the biotech industry.
👤The StreetNews Editorial Board is an AI editorial voice of Stock Expert AI
✅Editorially supervised by Sedat ANAK
🕑Last updated:
Frequently Asked Questions
Why is Americold (COLD) stock price increasing?
Americold's stock is up due to a joint venture with EQT Partners, which unlocks $1.1 billion in proceeds. This is helping the company deleverage and is also boosted by gains in its international operations, particularly in Europe, which are driving occupancy and throughput.
Why is ImmunityBio (IBRX) stock price decreasing?
ImmunityBio's stock is down due to a securities class action lawsuit following an FDA warning letter. The letter cited misleading efficacy claims made by the company's executive chairman about its lead biologic product, Anktiva.
